Effects of an oral contraceptive combination with or without androgen on mammary tissues: A study in rats

被引:35
作者
Jayo, MJ
Register, TC
Hughes, CL
Blas-Machado, U
Sulistiawati, E
Borgerink, H
Johnson, CS
机构
[1] Pathol Associates Int, Advance, NC 27006 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Comparat Med, Winston Salem, NC 27103 USA
[3] Cedars Sinai Med Ctr, Ctr Womens Hlth, Los Angeles, CA 90048 USA
[4] Oklahoma State Univ, Coll Vet Med, Dept Anat Pathol & Pharmacol, Stillwater, OK 74078 USA
[5] Bogor Agr Univ, Primate Res Ctr, Bogor, Indonesia
关键词
mammary glands; oral contraceptives; androgens; cell proliferation; progesterone receptor;
D O I
10.1016/S1071-5576(00)00059-9
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVES: Oral contraceptive (OC) therapy has long been known to produce hypoandrogenemia. However, androgens are not part of any OC therapy available to women. This project was designed to evaluate the effects of low-estradiol containing Oc, with or without methyltestosterone (MT), on cell proliferation and progesterone receptor (PgR) expression in mammary gland epithelia of virgin female rats. METHODS: Sixty rats were divided into four groups. One group received OCs, whereas a second group received OC plus MT. A third group of rats was treated with an antiandrogen to mimic the hypoandrogenemic effects caused by OC therapy. All treated groups were compared with age-matched untreated controls. RESULTS: After 15 weeks of treatment, no inflammatory, precancerous, or cancerous lesions were observed in any treatment group. OC plus MT therapy caused significant suppression of epithelial proliferation, a reduction in the number of proliferating cell nuclear antigen-labeled cells, and an increase in the number of PgR-labeled cells. CONCLUSIONS: Our results suggest that a medication containing an estrogen-progestin-androgen combination has antiproliferative effects in mammary glands of experimental animals that could prove to have breast-protective potential in women. (J Soc Gynecol Investig 2000;7:257-65) Copyright (C) 2000 by the Society for Gynecologic Investigation.
引用
收藏
页码:257 / 265
页数:9
相关论文
共 51 条
[31]   Recent oral contraceptive use and risk of breast cancer (United States) [J].
Newcomb, PA ;
Longnecker, MP ;
Storer, BE ;
Mittendorf, R ;
Baron, J ;
Clapp, RW ;
TrenthamDietz, A ;
Willett, WC .
CANCER CAUSES & CONTROL, 1996, 7 (05) :525-532
[32]   Sex hormone binding globulin expression and colocalization with estrogen receptor in the human Fallopian tube [J].
Noé, G .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1999, 68 (3-4) :111-117
[33]  
PETERSON CA, 1995, J BONE MINER RES, V10, P81
[34]  
PICHON MF, 1980, CANCER RES, V40, P3357
[35]   Oral contraceptive treatment inhibits the normal acquisition of bone mineral in skeletally immature young adult female monkeys [J].
Register, TC ;
Jayo, MJ ;
Jerome, CP .
OSTEOPOROSIS INTERNATIONAL, 1997, 7 (04) :348-353
[36]   ANIMAL-MODELS FOR THE STUDY OF BONE LOSS AFTER CESSATION OF OVARIAN-FUNCTION [J].
RODGERS, JB ;
MONIERFAUGERE, MC ;
MALLUCHE, H .
BONE, 1993, 14 (03) :369-377
[37]   ACNE, HIRSUTISM, AND ALOPECIA IN ADOLESCENT GIRLS - CLINICAL EXPRESSIONS OF ANDROGEN EXCESS [J].
ROSENFIELD, RL ;
LUCKY, AW .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1993, 22 (03) :507-532
[38]   Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [J].
Schairer, C ;
Lubin, J ;
Troisi, R ;
Sturgeon, S ;
Brinton, L ;
Hoover, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (04) :485-491
[39]   Risks of menopausal androgen supplementation [J].
Slayden, SM .
SEMINARS IN REPRODUCTIVE ENDOCRINOLOGY, 1998, 16 (02) :145-152
[40]   PLASMA TESTOSTERONE-BINDING PROTEINS IN THE DEVELOPING RAT [J].
SUZUKI, Y ;
SINOHARA, H .
STEROIDS, 1981, 38 (03) :263-270